MobileMax moves onto TASE

Herzliya-based start-up MobileMax Inc. successfully completed its initial public offering on the Tel Aviv Stock Exchange on Thursday, raising NIS 22 million in shares and options.

By MATTHEW KRIEGER
June 11, 2007 07:36

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Herzliya-based start-up MobileMax Inc. successfully completed its initial public offering on the Tel Aviv Stock Exchange on Thursday, raising NIS 22 million in shares and options. The company, which was founded by Raanan Cohen in 2004 and is valued at NIS 98m., is owned 11.5% by Leon Recanati's GlenRock Israel; 8% each by Colmobil Ltd. Managing Director Yoav Harlap and Arie Saban; and 6% each by former Israel Phoenix Assurance Chairman Joseph Hackmey and Eli Elroy. MobileMax develops, produces and markets software and hardware that enable low-cost international calls from mobile telephones.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS